Bain commits $300M to advance Cardurion’s CV programs

With nearly twice as much capital in its latest fund than in its predecessor, Bain Capital Life Sciences is making a splash with the fund’s first big investment, co-leading a $300 million financing in cardiovascular play Cardurion.

Following its 2017 spinout from Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Cardurion Pharmaceuticals LLC now has the financial firepower to push its two lead programs to clinical proof-of-concept and add to the pipeline via business development...